Cytiva, a life sciences company based in Marlborough, Massachusetts, has acquired West Jordan’s Intermountain Life Sciences (ILS). ILS manufactures high-purity water, buffers and liquid cell culture media.
Cytiva said it intends to use ILS’ Utah manufacturing site to rapidly boost its liquid cell culture production by millions of liters. The company has begun hiring workers to facilitate a rapid increase in output.
“The demand for buffers and cell culture media has grown substantially in recent years thanks to their use in gene therapies, as well as their use in making COVID-19 vaccines and therapies,” said Olivier Loeillot, vice president of Cytiva. “Adding the capacity and talent from Intermountain Life Sciences will allow us to accelerate deliveries to our customers.”
Intermountain’s site is already fully functional and running efficiently, Loeillot said. “We’re really impressed with the quality practices that we see and we’ll be bringing dozens of people on board to build on the work already being done at the site.”
“At Intermountain, we aim to be an innovative, responsive and quality-driven outsourcing partner to the biotechnology industry,” said Russ Wilcox, president of Intermountain. “As part of Cytiva, we’ll continue on this mission at a larger scale.”
The Intermountain site in Utah and its capabilities will become part of Cytiva’s cell culture media portfolio, which has a 40-plus year history in the Cache Valley and currently employs more than 700 people at its Logan facilities.
Intermountain Life Sciences was established in 2014 as a facility for manufacturing water for pharmaceutical purposes and custom process solutions for use in a broad spectrum of scientific research, medical device and biopharmaceutical manufacturing applications.
